样本溯源检测可识别影响前列腺癌活检标本分子预后检测结果的污染
本研究评估了2134例来自单一大型泌尿外科诊所的病例,使用短串联重复序列分析进行DNA样本溯源验证,检测是否存在显著水平的污染DNA。结果显示49例(2.3%)存在显著污染,其中5例去污染后重测细胞周期进展(CCP)评分,平均绝对变化0.48,足以影响患者10年死亡率计算及主动监测决策。
要点
- 未染色组织切片中DNA污染发生率为2.3%。
- 污染可导致CCP评分变化,平均绝对变化0.48。
- 污染程度足以影响主动监测的临床决策。
核心结论
- 送往预后分子诊断检测的前列腺癌未染色组织切片中DNA污染发生率为2.3%,且污染程度可影响结果及后续主动监测适宜性的临床决策。
研究设计与样本
- 单中心大型泌尿外科诊所2134例病例,采用短串联重复序列分析进行DNA样本溯源验证。
主要发现
- 2134例中49例(2.3%)存在显著水平污染DNA。
- 49例中7例去污染后重送分子诊断检测,其中5例前列腺癌标本有足够组织和RNA给出更准确的细胞周期进展(CCP)评分。
- 这5例患者CCP评分平均绝对变化0.48,最小差异0.1单位,最大差异1.0单位。
- CCP评分变化足以导致患者按综合风险评分计算的10年死亡率发生有意义的改变。
临床怎么用
- 对送检前列腺癌预后分子检测的未染色组织切片,应考虑进行DNA样本溯源验证以识别污染。
- 去污染后重测可提高CCP评分准确性,避免污染影响主动监测决策。
局限性
- 去污染后仅5例标本有足够组织和RNA进行CCP评分重测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine if tissue contamination in histologic specimens can significantly affect the results of prognostic molecular markers that are routinely used as confirmatory tests to safely assign appropriate candidates to prostate cancer active surveillance protocols. MATERIALS AND METHODS: This study evaluates 2134 cases from a single, large urology practice that were successfully tested for DNA specimen provenance verification using short tandem repeat analysis for the presence of a significant level of contaminating DNA. After removal of the contamination, 5 of the samples were retested, and the results of the molecular diagnostic test were compared. RESULTS: Forty-nine of the 2134 cases (2.3%) sent for DNA provenance analysis were found to possess significant levels of contamination. Of these 49 cases, 7 were resent for a repeat molecular diagnostic test after being decontaminated. Five of these prostate cancer specimens had sufficient tissue and RNA to give a more accurate cell cycle progression (CCP) score. The average absolute change in these patients' CCP scores was 0.48, with a minimum of 0.1-unit and a maximum of 1.0-unit difference. These changes in CCP scores are significant enough to cause meaningful alterations in a patient's calculated 10-year mortality rate, as defined by their combined risk score. CONCLUSION: DNA contamination in unstained tissue sections sent for prognostic prostate cancer molecular diagnostic testing occurs in 2.3% of the cases, and can be of a magnitude that affects the results and subsequent clinical decision of appropriateness for active surveillance.
引用
- Wojno L, Minutella C, Moylan D, et al. Specimen Provenance Testing Identifies Contamination That Affects Molecular Prognostic Assay Results in Prostate Cancer Biopsy Specimens. Urology. 2018. PMID: 29476774. doi:10.1016/j.urology.2018.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。